Table 2.

Testosterone deficiency in testicular cancer patients after completion of treatment

Study	Number of patients (n)	Threshold for testosterone (T) concentration (LLN)	Median T concentration after the treatment	Percentage of patients with testosterone deficiency (%)
Pühse et al. [13]	160	9.85 nmol/L	NA	11–33
Nord et al. [14]	1183	8 nmol/L	16.7 (14.8–18.7) nmol/L	NA
Eberhard et al. [15]	143	10 nmol/L	13 (3–22) nmol/L	NA
Berger et al. [16]	63	3 ng/mL	5 (1.5–11.1) ng/ml	17
Gerl et al.a [17]	117	10 nmol/L	16.3 (6.0–55.7) nmol/L	11
Lackner et al. [18]	83	3 ng/mL	NA	25.3
Ondrusova et al. [19]	823	12 nmol/L	NA	15.1
Wiechno et al. [20]	326	2.6 ng/mL	0.2–11.8 ng/mL	15
O’Carrigan et al. [21]	54	8 nmol/L	13 nmol/L	13
Willemse et al.b [22]	176b	8 nmol/L	6.4–32.1 nmol/L	17.6

T testosterone, LLN lower limit of normal, NA not available

^a Patients undergoing surgery with subsequent chemotherapy, with cumulative cisplatin dose of max. 400 mg/m², median values

^b Patients undergoing combination chemotherapy, hypogonadism defined as T < 10 nmol/L